Noneconomic Damages Caps Cut Malpractice Payments by 15%

This article originally appeared here.
Share this content:
Noneconomic Damages Caps Cut Malpractice Payments by 15%
Noneconomic Damages Caps Cut Malpractice Payments by 15%

(HealthDay News) -- Adoption of noneconomic damages caps reduces average malpractice payments by 15 percent, according to research published in the October issue of Health Affairs.

Seth A. Seabury, Ph.D., from the University of Southern California in Los Angeles, and colleagues estimated the impact of state noneconomic damages caps on average malpractice payment size using data from a national sample of malpractice claims for 1985 to 2010. They compared how the impact differed with cap restrictiveness ($250,000 versus $500,000).

The researchers found that, compared with having no cap, noneconomic damages caps reduced the average payments by 15 percent ($42,980). Compared with having no cap, average payments were reduced by 20 percent ($59,331) with a more restrictive $250,000 cap, while a less restrictive $500,000 cap had no significant impact. Physician specialty influenced the effect of the cap, with the largest impact on claims involving pediatricians and the smallest impact for claims involving surgical subspecialties and ophthalmologists.

"Future evaluations of malpractice reforms and the design of malpractice policy should consider both the types of physicians who are most likely to be affected by reforms and the differential impact that reforms may have depending on how restrictive they are," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »